App-Quantinova.ai

Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Haematopoietic Cell Transplantation: Extended Follow‐Up of the Phase 2 Multi‐Cohort CheckMate 205 Study

G. Collins - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Adcetris

Modification of escalated BEACOPP through Dacarbazine substitution for Procarbazine potentially shortens the time to post treatment menstrual cycle recovery and reduces red cell transfusion requirements

A. Santarsieri - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hodgkin's Lymphoma

Erythropoietin

“Immuno‐flowFISH”: Diagnostic assessment of structural chromosomal abnormalities in phenotyped chronic lymphocytic leukaemia cells by imaging flow cytometry

K. Clarke - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

N/A

Significance of incidental findings detected on PET‐CT scans performed in haemato‐oncology: a single centre experience

C. Mackintosh - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hodgkin's Lymphoma

N/A

Long‐term ibrutinib therapy reverses CD8 + T cell exhaustion in B cell chronic lymphocytic leukaemia

H. Parry - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Ibrutinib

Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with > 1 Year Prior Ibrutinib Exposure

T. Munir - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Obinutuzumab

Switched memory B‐cells as a marker for identifying haemato‐oncology patients who require immunoglobulin replacement therapy for secondary immunodeficiency

A. Shields - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Hypogammaglobulinaemia

N/A

Evaluation of the diagnostic usefulness of CD200 marker in Chronic Lymphocytic Leukaemia and mature B‐cell lymphoproliferative disorders

N. Soong - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

N/A

Efficacy of R‐BAC immunochemotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy

R. McCulloch - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Mantle cell lymphoma

ACP-196

Ifosfamide‐based regimens for lymphoma are safely administered in an ambulatory care setting: an audit of ifosfamide‐induced encephalopathy in a single tertiary centre

W.Y. Chan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Encephalopathy

Methylthioninium chloride

Nivolumab, Brentuximab Vedotin, and Bendamustine as Response‐Adapted Treatment for Relapsed or Refractory Hodgkin Lymphoma in Children, Adolescents and Young Adults: Results from the Standard‐Risk Cohort of the Phase 2 Checkmate 744 Study

P. Harker-Murray - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Hodgkin's Lymphoma

Adcetris

Studying the molecular mechanisms of resistance to the irreversible, covalent BTK inhibitor, Tirabrutinib

R. Jackson - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Tirabrutinib

Indirect Treatment Comparison of Venetoclax plus Rituximab with B‐cell Receptor Inhibitors in Patients with Relapsed/Refractory Chronic Lymphocytic Leukaemia

A. Mato - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Bendamustine

Circulating tumour DNA analysis to detect clonal evolution in TP53 mutated CLL treated with sequential precision medicines

C.S. Trethewey - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Tirabrutinib

R‐DA EPOCH in High Risk Diffuse Large B cell lymphoma: a multicentre experience from the East of England

D. Sparksman - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Epoch

Evaluation of the detection of B‐cell clonal lymphoproliferative disorders by flow cytometry or cytological analysis in lymph node aspirates obtained by endobronchial ultrasound

O. Lomas - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Lympho proliferative disease

N/A

Efficacy of Mogamulizumab by Prior Systemic Therapy in Patients With Previously Treated Cutaneous T‐Cell Lymphoma: Post Hoc Analysis From the Phase 3 MAVORIC Study

J. Scarisbrick - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mycosis fungoides

Interferon alpha

Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin, etoposide (ICE) chemotherapy

T. Tay - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral T-cell lymphoma

Carboplatin

Non‐Hodgkin Lymphoma in Older Teenagers and Young Adults. A national prospective population‐based study

R. Carr - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Diffuse large B-cell lymphoma

N/A

Myeloma‐specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth

G. Stewart - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Bortezomib

Filters

45280 Abstracts